Development and evaluation of an automated hepatitis C virus NS5B sequence-based subtyping assay

Virco BVBA, Mechelen, Belgium.
Clinical Chemistry and Laboratory Medicine (Impact Factor: 2.96). 08/2010; 48(8):1095-102. DOI: 10.1515/CCLM.2010.236
Source: PubMed

ABSTRACT Hepatitis C virus (HCV) genotyping and accurate subtype determination is becoming increasingly important to better understand viral evolution, the development of resistance to STAT-C, and possibly even for the treatment and management of chronic HCV-infected patients.
A subtyping assay based on a 329-bp sequence of the NS5B region, together with an automated subtype interpretation tool was developed. Clinical samples of the six major genotypes were used to assess assay performance characteristics.
The NS5B BLAST-based subtyping assay showed clinical sensitivity for amplification of 89% (n=603 random samples). Assessment of analytical sensitivity of amplification for genotypes 1, 2, 3 and 4 revealed a suitable performance for high viral load samples and decreased only with low viral loads. The results were 100% and 99% accurate at the genotype and subtype level, respectively. A concordance of 97% on genotype level and 62% on subtype level was observed by comparison with subtype results from 5' non-coding-based assays with a panel of 276 isolates.
The HCV NS5B subtyping assay has been validated for research use. Based on its performance, it is the method of choice in cases where subtype rather than genotype information is needed.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract The present study describes the strains of hepatitis C virus (HCV) isolated from Tunisian hemodialysis patients. Thirty-three HCV strains isolated from different dialysis centers in Tunis City were amplified by RT-PCR in a region of the NS5b gene, genotyped by sequencing, and compared to international sequences by phylogenetic analysis. The phylogenetic tree showed that 16 HCV isolates have been identified as subtype 4k (48.5%), 7 as unspecified HCV-4 subtype (21.2%), 5 as subtype 4a et 1b (each 15.2%). The analysis of this tree revealed that the HCV-1b strains were closely related to Anglo-Saxon and European isolates, while the HCV-4 isolates are genetically similar to Egyptian and African strains. Phylogenic analysis of 33 Tunisian isolates with international HCV strains on a region of the NS5b gene demonstrated that the subtype 4k submerged the Tunis city and a new subtype of HCV4 seems to be suspect in this area.
    Viral immunology 02/2013; 26(1). DOI:10.1089/vim.2012.0043 · 1.64 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction:Accurate genotyping of hepatitis C virus (HCV) is important in determining the optimal regimen, dose and duration of antiviral therapy of chronic HCV, as well as estimating the response rate. The 5-untranslated region (5'UTR) of HCV RNA is used in commercial genotyping, but probes and lengths of amplicons are proprietary and vary across assays.Objective:Evaluation of the HCV 5'UTR for factors involved in reliable determination of HCV genotypes.Study Design:Serum from four subjects with chronic HCV with disparate results on commercial genotyping and four controls were analyzed. HCV RNA was extracted from serum samples and the 5'UTR and NS5B region were sequenced. Ten clones from each region were compared to prototype sequences and analyzed for genotype assignment using five programs. Results were compared to commercial assays. 5'UTR sequences were sequentially shortened from either the 5' end or 3' end, or both, with genotyping of resultant fragments.Results:Sequences were obtained for the 5'UTR in all eight subjects, but for the NS5B in five. Genotype assignment was identical between the two regions in those 5 with complete sequencing. Genotyping by sequencing gave different results from the commercial assays in the four experimental samples but agreed in the four controls. Shortening of sequences affected results and sequences of less than 200 bases were inaccurate. Neither Hamming distance nor quasispecies affected results.Conclusion:Sequencing of the HCV 5'UTR provided reliable genotyping results and resolved discrepancies identified in commercial assays, but genotyping by sequencing was highly dependent upon sequence length.
    Journal of clinical microbiology 03/2013; 51(5). DOI:10.1128/JCM.03344-12 · 4.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Hepatitis C virus (HCV) genotyping is mandatory for tailoring dose and duration of pegylated interferon-α plus ribavirin treatment and for deciding on triple therapy eligibility. Additionally, subtyping may play a role in helping to select future treatment regimens that include directly-acting antivirals. However, commercial assays for HCV genotyping fail to identify the genotype/subtype in some cases. OBJECTIVE: Our aims were (i) to determine the success rate of the commercial genotyping assay Abbott RealTime HCV Genotype II at identifying the genotype and the HCV-1 subtype; and (ii) to phylogenetically characterise the obtained indeterminate results. STUDY DESIGN: HCV genotyping results obtained between 2009 and 2012 in a Spanish reference hospital were reviewed. A total of 896 people were genotyped with the Abbott RealTime HCV Genotype II assay. Specimens with an indeterminate result were retrospectively genotyped using the reference method based on the phylogenetic analysis of HCV NS5B sequences. RESULTS: Using the commercially available assay, an indeterminate HCV genotype result was obtained in 20 of 896 patients (2.2%); these corresponded to genotypes 3a, 3k and 4d. Importantly, 8.6% of all cases where genotype 3 was detected were indeterminate. In addition, the HCV-1 subtype was not assigned in 29 of 533 cases (5.4%). CONCLUSIONS: The implementation in the clinical microbiology laboratory of the reference method for HCV genotyping allows indeterminate genotype/subtype results to be interpreted and may lead to the identification of previously uncharacterised subtypes.
    Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 05/2013; 58(3). DOI:10.1016/j.jcv.2013.05.005 · 3.47 Impact Factor